AS1411 aptamer-modified theranostic liposomes co-encapsulating manganese oxide nano-contrast agent and paclitaxel for MRI and therapy of cancer

Li, Jingjing; Li, Qing; He, Meijuan; Fan, Daiming; Cai, Lulu; Zhao, Mingming; Dong, Lei; Wang, Qi; Xu, Kai

doi:10.1039/c9ra06878c

Cited by 22 publications

(12 citation statements)

References 63 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liposome-PEG-MnO-PTX is a liposome-based nanoparticle for chemo-radiation therapy. In this study, the effectiveness of manganese oxide as a radiation sensitizer was clearly shown in tumour therapy, where the lipo-MnO-PTX group had signi cant tumour reduction compared to the lipo-PTX group [27]. Similar to our study, Mn 3 O 4 was used for cancer therapy in the form of Mn 3 O 4 @Au-dsDNA/DOX, where dsDNA is used to activate the interferon gene pathway and doxorubicin (DOX) is chemotherapeutic.…”

Section: Discussionsupporting

confidence: 76%

Lipo-MGN Nanoparticle Hypoxia Attenuation Mediated Single-dose Radiotherapy and pH/ROS Responsive T1 Contrast Magnetic Resonance Imaging in Hepatocellular Carcinoma

Thomas

Kim

Nagareddy

et al. 2022

Preprint

View full text Add to dashboard Cite

Tumour hypoxia is an important factor for developing resistance to radiation therapy (RT) and present a bleak prognosis in cancer patients undergoing treatment for RT resistant hepatocellular carcinoma. Here, we present the synthesis of liposome-coated Mn3O4 (MGN) nanoparticles (Lipo-MGN) and investigation of their therapeutic potential with RT utilizing a HepG2 cancer model. According to in-vitro research, Lipo-MGN effectively produced oxygen in the presence of H2O2 and significantly reduced the expression of HIF-1 in human HepG2 cells that were under hypoxic conditions. Lipo-MGN reversed the radio-resistance brought on by hypoxia and increased cell damage. When Lipo-MGN and RT were administered together in a HepG2 xenograft mice model, the tumor growth was delayed more than with RT alone. As determined by histochemistry, liposome-MGN also inhibited tumor angiogenesis. According to these findings, Lipo-MGNs may increase the impact of RT by simultaneously focusing on angiogenesis and tumor hypoxia. Hypoxic, radioresistant HepG2 cancer may be treated with Lipo-MGN in clinical studies.

show abstract

Section: Discussionsupporting

confidence: 76%

Lipo-MGN Nanoparticle Hypoxia Attenuation Mediated Single-dose Radiotherapy and pH/ROS Responsive T1 Contrast Magnetic Resonance Imaging in Hepatocellular Carcinoma

Thomas

Kim

Nagareddy

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Blank liposomes were prepared by lipid film hydration and extrusion method, according to the article we previously published with minor modification [ 21 ]. Briefly, 0.0198 g DSPC, 0.0048 g cholesterol, 0.001875 g DSPE-mPEG2000 and 0.001875 g DSPE-mPEG2000-COOH were dissolved in a mixture of chloroform (4 mL) and methanol (1 mL).…”

Section: Methodsmentioning

confidence: 99%

Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect

et al. 2022

Self Cite

View full text Add to dashboard Cite

Macrophages participate in many links in the pathological process of atherosclerosis (AS) and the regulation of influence of macrophages at the molecular level might be a new avenue for AS treatment. For this aim, the macrophage membrane biomimetic nanoparticles, derived from macrophage membrane coated SHP1i-loaded liposome NPs (MM@Lips-SHP1i) was designed. Due to the reservation of intrinsic membrane proteins and function from macrophages, the biomimic nanoparticles could effectively evade clearance by the immune system, prolong blood circulation time and actively tend and aggregate to atherosclerotic plaques. More importantly, in the plaque area, MM@Lips-SHP1i nanoparticles could compete with macrophages in vivo to bind with oxidized low-density lipoprotein (oxLDL) and lipopolysaccharide (LPS), reduce uptake of new lipids by macrophages, reduce foam cell formation, and inhibit the expression of pro-inflammatory cytokines. In addition, small molecule inhibitor of SHP-1, the downstream effector molecule of CD47 loaded in macrophage membrane biomimetic nanoparticles could interrupt CD47-SIRPα signal transduction in monocytes and macrophages, thereby enhancing the efferocytosis of macrophages, inhibiting the progression of plaque, achieving synergistic treatment of atherosclerosis. This work focuses on the key process in the formation of AS, macrophage foaming and chronic inflammation, and is based on the fact that macrophage membrane biomimetic nanoparticles can preserve the key surface proteins of macrophages closely related to the formation of AS, providing a new avenue to inhibit the progression of AS by utilizing the biological characteristics of macrophage membrane in macrophage membrane biomimetic nanoparticles.

show abstract

“…For example, researchers have confirmed that PEG‐EGCG can be used for both drug delivery and collaborative treatment. [ 76 ] Other synthetic polymer materials, such as tPF@PCM, can enhance the effectiveness of photothermal tumor inhibition. [ 75 ] Natural nanomaterials with excellent biocompatibility can improve the efficacy of traditional drugs, which will reduce their toxicity.…”

Section: Discussionmentioning

confidence: 99%

Advanced Nanomaterials for the Diagnosis and Treatment of Renal Cell Carcinoma

Chen

Mei

et al. 2022

Advanced NanoBiomed Research

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is the most common type of kidney cancer. Owing to the high morbidity rate of RCC, there is an urgent need for intensive research on robust materials to diagnose and treat RCC. Nanomaterials have been developed largely in the last three decades because of their numerous advantages, such as high specific surface area, simple surface functionalization, rapid onset of therapeutic action, superior biological activity, and other unique physical–chemical characteristics. Herein, first, various types of nanomaterials used in RCC treatment are introduced, including inorganic nanomaterials, lipid nanomaterials, synthetic polymer nanomaterials, and natural nanomaterials. Second, the different diagnosis and therapeutic mechanisms of nanomaterials in the kidneys are reviewed and these advantages of nanomaterials are highlighted. Furthermore, nanomaterials are investigated for the preclinical and clinical detection and treatment of RCC. Finally, the challenges and outlook of various nanomaterials for RCC diagnostic and treatment are discussed.

show abstract

AS1411 aptamer-modified theranostic liposomes co-encapsulating manganese oxide nano-contrast agent and paclitaxel for MRI and therapy of cancer

Abstract: AS1411 aptamer modified theranostic liposomes co-encapsulating manganese oxide nano-contrast agent and paclitaxel for MRI and therapy of cancer was realized.

Cited by 22 publications

References 63 publications

Lipo-MGN Nanoparticle Hypoxia Attenuation Mediated Single-dose Radiotherapy and pH/ROS Responsive T1 Contrast Magnetic Resonance Imaging in Hepatocellular Carcinoma

Lipo-MGN Nanoparticle Hypoxia Attenuation Mediated Single-dose Radiotherapy and pH/ROS Responsive T1 Contrast Magnetic Resonance Imaging in Hepatocellular Carcinoma

Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect

Advanced Nanomaterials for the Diagnosis and Treatment of Renal Cell Carcinoma

Contact Info

Product

Resources

About